Dublin, Ireland-based Allergan announced it will acquire San Francisco-based Oculeve for a $125 million upfront payment plus milestone payments related to Oculeve’s lead development program OD-01, a device to treat dry eye disease. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program.

Full Story